|
 |
LuxiqThis page contains recent news articles, when available, and an overview of Luxiq but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Luxiq (when available) Betamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, or betamethasone valerate for the treatment of inflammation due to corticosteroid-responsive dermatoses. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections. For relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses Mechanism Of Action: Betamethasone is a glucocorticoid Receptor Agonist. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Betamethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin. News Articles on Betamethasone Event Brief of Q4 2004 Connetics Earnings Conference Call - Part 1. - Jan 25, 2005 ...s existing product prescriptions for Luxiq, OLUX, and Soriatane were encouraging. 2. ... The Co. is seeing Luxiq and OLUX franchise growing at close to 10%, ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Connetics Announces First Quarter Results with Product Sales up 79 … - Apr 26, 2005 First quarter 2005 sales of OLUX and Luxiq were $21.4 million, representing an increase of 8% over the same period in 2004. Soriatane sales were $17.6 ... $4.95 - Business Wire - ECNext Alliance aims at foam-based treatment for scabies - Sep 22, 2005 Most foam dosage forms used in dermatology to date have incorporated corticosteroids, notably Connetics' Luxiq (betamethasone) formulation for scalp ... In-PharmaTechnologist.com Event Brief of Q1 2006 Connetics Earnings Conference Call - Part 1. - May 3, 2006 Since CNCT began selling its first product, Luxiq in 1999, ... CNCT saw meaningful market share increases for both Evoclin and Luxiq in the called on ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Perrigo to invest $12.5M in Pentech entity - May 21, 2008 Pentech's ANDA for Luxiq included a Paragraph IV certification, which indicates that the generic drug would infringe an existing patent, but claims that the ... Boston Globe Finance; Dermatology company reports Q4 net income of $6.4M; product ... - Feb 22, 2005 Combined OLUX and Luxiq revenues increased 19% compared with the fourth quarter of 2003. Selling, general, and administrative (SG&A) expenses increased to ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Finance; Dermatology company reports Q4 net income of $6.4M; product ... - Feb 25, 2005 Combined OLUX and Luxiq revenues increased 19% compared with the fourth quarter of 2003. Selling, general, and administrative (SG&A) expenses increased to ... Pay-Per-View - Drug Week - Factiva, from Dow Jones FDA Approves Connetics' Verdeso Foam for the Treatment of Mild-to- … - Sep 19, 2006 In addition to Verdeso, Connetics' VersaFoam-based products are OLUX for scalp dermatoses and non-scalp psoriasis, Luxiq Foam for scalp dermatoses and ... Free with registration - Business Wire - AccessMyLibrary.com Event Brief of Q4 2005 Connetics Earnings Conference Call - Final. - Jan 31, 2006 4Q05 prescriptions for Olux and Luxiq slightly below expectations. 4. ... Luxiq had a 3% YoverY growth rate. 3. Soriatane had a 2% YoverY growth rate. 4. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Ventiv Announces New Partnership with Connetics Corporation; … - Apr 14, 2005 Luxiq (betamethasone valerate) Foam, 0.12%, is a mid-potency corticosteroid, delivered in ... Luxiq is available in 50g, 100g and 150g trade unit sizes. ... $4.95 - PR Newswire - ECNext Press Release: Perrigo Company Announces Collaborative Agreement … - May 21, 2008 Pentech filed its ANDA for Luxiq foam containing a Paragraph IV Certification with the U.S. Food & Drug Administration and notified Connetics, ... Pay-Per-View - PR Newswire - HighBeam Research Business & Finance; Dermatology company reports fourth-quarter … - Mar 7, 2006 We see immediate opportunity in this market for Evoclin and Luxiq, and later this year for Desilux, if FDA [US Food & Drug Administration] approval is ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Connetics Second Quarter Revenues Increase 19 Percent; OLUX, … - Aug 2, 2005 Sales of Luxiq during the quarter totaled $5.8 million. Selling, general and administrative expenses for the second quarter of 2005 increased to $25.1 ... $4.95 - Business Wire - ECNext Press Release: Starpharma Signs Collaborative Research Agreement … - Dec 3, 2007 Topical Gel, MimyX(TM) Cream, Olux(R ... R), Evoclin(TM), Verdeso(TM) and Luxiq(R ... around the world. Stiefel Laboratories supplements its R ... ... Pay-Per-View - PR Newswire - HighBeam Research Connetics Reports Second Quarter Financial Results. - Aug 14, 2006 Second quarter 2006 revenues include Soriatane(R) sales of $16.3 million, OLUX(R) sales of $12.2 million, Evoclin(R) sales of $9.3 million and Luxiq(R) ... $4.95 - Business Wire - ECNext New Rogaine(R) Foam Features Connetics' Proprietary VersaFoam(R) … - Sep 5, 2006 Connetics' VersaFoam-based products are OLUX(R) for scalp dermatoses and non-scalp psoriasis, Luxiq(R) Foam for scalp dermatoses and Evoclin(R) Foam for the ... Free with registration - Business Wire - AccessMyLibrary.com Q1 2006 Connetics Earnings Conference Call - Final. - May 3, 2006 Since we began selling our first product, Luxiq, in 1999 we've taken quarterly reserves to account for rebate obligation. However, as Connetics' business ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Company Profile Report - Dec 16, 2006 The Company markets four pharmaceutical products, Luxiq (betamethasone valerate) Foam, ... Olux (Clobetasol Propionate); Luxiq (Betamethasone Valerate) Foam ... $50.00 - Revere Reports - Revere Connetics Reports Positive Results From Desilux Phase III Trial; NDA ... - Aug 15, 2005 ..."We have established leading brands in the topical mid- and super-high potency steroid categories with Luxiq and OLUX, respectively, and with Desilux ... $4.95 - Business Wire - ECNext Drug/Medical Device - Dec 16, 2006 The Company markets four pharmaceutical products, Luxiq (betamethasone valerate) ... Luxiq (Betamethasone Valerate) Foam, Relief Of The Inflammatory And ... $70.00 - Revere Reports - Revere Connetics Reports Highlights of 2005 Analyst and Investor Day;... - Apr 14, 2005 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... $4.95 - Business Wire - ECNext Business & Finance; Connetics reports preliminary results for first... - May 31, 2006 ..."In addition, we completed our acquisition of a pediatric sales force, which is now trained and in the field promoting Evoclin and Luxiq. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones ë°”ë¥¸ì–¸ë¡ ë¹ ë¥¸ë‰´ìŠ¤ ì?¸í„°ë„· 연합뉴스 - May 7, 2008 5%):ì—?ë³´í?´ë¦°(í?´ë¦°ë‹¤ë¯¸ì‹ ì?¸ì‚°)í?¼, 1%: Luxiq(R) (ë² íƒ€ë©”íƒ€ì†? valerate) Foam, 0.12%; MimyX(R)í?¬ë¦¼; Olux(R) (clobetasol propionate) Foam, 0.05% 와 Olux(R) ... 연합뉴스 Competitors by Product Report - Dec 16, 2006 The Company markets four pharmaceutical products, Luxiq (betamethasone valerate) Foam, ... Olux (Clobetasol Propionate); Luxiq (Betamethasone Valerate) Foam ... $75.00 - Revere Reports - Revere Stiefel Laboratories Will Enter Into Private Equity Minority Investmen... - Aug 9, 2007 5%); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R); Olux(TM) (clobetasol propionate) Foam, 0.05%; ... Free with registration - PR Newswire - AccessMyLibrary.com æ–°å?Žç¾Žé€šæ¶ˆæ?¯ï¼šStiefelLaboratories任命首任首å¸ç§‘å¦å®˜ - Apr 8, 2008 Gel(ç›?é…¸å…‹æž—éœ‰ç´ ï¼Œ1% -过氧化苯甲酰，5%)ï¼›Evoclin®(å…‹æž—éœ‰ç´ ç£·é…¸é…¯)Foam，1%ï¼›Luxiq®( å€?ä»–ç±³æ?¾æˆŠé…¸é…¯)Foam，0.12%ï¼›MimyX® Cream；也å?¯åœ¨Olux®/Olux-Eâ„¢ COMPLETE ... ä¸é‡‘在线 Stiefel Laboratories Receives FDA Approval of Olux-E (Clobetasol … - Jan 23, 2007 Products formulated with VersaFoam-HF include: Olux® (clobetasol propionate) Foam, 0.05%; Luxiq® (betamethasone valerate) Foam, 0.12%; and Evoclin® ... DG News Stiefel Laboratories 任命首任首å¸ç§‘å¸å®˜ - Apr 8, 2008 ...ä¸ç?²å¾—çš„Duac(R) Topical Gelï¼ˆé¹½é…¸å…‹æž—éœ‰ç´ ï¼Œ1% -é?Žæ°§åŒ–苯甲□，5%）﹔Evoclin(R)（ å…‹æž—éœ‰ç´ ç£·é…¸é…¯ï¼‰Foam，1%ï¹”Luxiq(R)（å€?ä»–ç±³æ?¾æˆŠé…¸é…¯ï¼‰Foam，0.12%ï¹”MimyX(R) ... 財è?¯ç¶² DUSA Expands Global Sales With Launch of Levulan ® Kerastick ® in … - Oct 1, 2007 1%; Luxiq ® (betamethasone valerate) Foam, 0.12%; MimyX ® ; Olux TM (clobetasol propionate) Foam, 0.05%; Olux-E TM (clobetasol propionate) Foam, 0.05%; ... marketwire.com ×”× ×¤×˜ והדיור שלחו ×?ת וול סטריט לירידות: מדד S&P 500 × ×—×œ×© ב-1.3% והש? - May 23, 2008 ...ל×?שר גירסה ×’× ×¨×™×ª לקצף Luxiq שפיתחה חברת ×§×•× ×˜×™×§×¡ (Connetics), ומשמש לטיפול בדלקת עור בקרקפת. ... ×”×?רץ FDA Approves Extina(R) for the Treatment of Seborrheic Dermatitis - Jul 17, 2007 5%); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R) Cream; Olux(TM) (clobetasol propionate) Foam, ... RedOrbit Stiefel Laboratories, Inc. Kuasai ABR Invent dan ABR Development - May 7, 2008 ...lima persen) tersedia di Sistim Perawatan Duac(R); Evoclin(R) (clindamycin fosfat) Foam, satu persen; Luxiq(R) (betametason valerate). ... ANTARA Stiefel Laboratories, Inc. Enters into Strategic Collaboration with... - Nov 6, 2007 Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R); Olux(TM) (clobetasol propionate) Foam, 0.05%; ... Free with registration - PR Newswire - AccessMyLibrary.com Stiefel Laboratories Angkat Kepala Ilmiah Utama - Apr 8, 2008 ...lima persen) tersedia di Sistem Perawatan Duac (R); Evoclin(R) (clindamycin fosfat) Foam, satu persen; Luxiq(R) (betametason valerate). ... ANTARA TOP TALENT AND RAPID R&D PUT CONNETICS ON FAST TRACK - - Apr 11, 2005 Connetics has four drugs on the market: Luxiq for scalp ailments, Evoclin for acne, OLUX for moderate psoriasis and Soriatane for severe psoriasis. ... $2.95 - San Jose Mercury News - NewsBank President leaves PediaMed after sales force sold - Feb 27, 2006 Connetics said the PediaMed group would begin selling Evoclin (clindamycin) Foam, 1 percent, a topical treatment for acne, and Luxiq (betamethasone ... Bizjournals.com Stiefel Laboratories 收購ABR Invent å’ŒABR Development - May 7, 2008 ...ä¸ç?²å¾—çš„Duac(R) Topical Gelï¼ˆé¹½é…¸å…‹æž—éœ‰ç´ ï¼Œ1% -é?Žæ°§åŒ–苯甲□，5%）﹔Evoclin(R)（ å…‹æž—éœ‰ç´ ç£·é…¸é…¯ï¼‰Foam，1%ï¹”Luxiq(R)（å€?ä»–ç±³æ?¾æˆŠé…¸é…¯ï¼‰Foam，0.12%ï¹”MimyX(R) ... 財è?¯ç¶² Stiefel Laboratories Moves to Solidify, Enhance Its Leadership... - Apr 23, 2007 5%); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(TM) Cream; Olux(R) (clobetasol propionate) Foam, ... $4.95 - PR Newswire - ECNext DermTech and Stiefel Laboratories, Inc. Begin Feasibility Study to … - Jan 7, 2008 5%) Topical Gel; Evoclin(R) (clindamycin phosphate, 1%) Foam; Luxiq(R) (betamethasone valerate, 0.12%) Foam; MimyX(R); Olux(TM) (clobetasol propionate, ... Free with registration - PR Newswire - AccessMyLibrary.com Stiefel Laboratories, Inc. Donates First Dermatology Ward in Tanzania,... - Feb 1, 2007 Duac(R) Topical Gel, MimyX(TM) Cream, Olux(R), Brevoxyl(R) Creamy Wash, Oilatum(R), Soriatane(R), Evoclin(TM), Verdeso(TM) and Luxiq(R). ... $4.95 - PR Newswire - ECNext Connetics Files Patent Infringement Lawsuit Against Agis, a Wholly- … - Oct 20, 2005 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... RedOrbit Stiefel Laboratories, Inc. Enters into Strategic Collaboration with... - Nov 6, 2007 Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R); Olux(TM) (clobetasol propionate) Foam, 0.05%; ... $4.95 - PR Newswire - ECNext DUSA Announces Stiefel's Receipt of Pricing Approval of Levulan PDT... - Mar 6, 2008 1%; Luxiq ® (betamethasone valerate) Foam, 0.12%; MimyX ® ; Olux TM (clobetasol propionate) Foam, 0.05%; Olux-E TM (clobetasol propionate) Foam, 0.05%; ... marketwire.com Stiefel Plans $640M Acquisition Of Dermatology Firm Connetics - Oct 24, 2006 The company turned its attention to such products as Olux (clobetasol propionate) and Luxiq (betamethasone valerate) foams, marketed for scalp dermatoses. ... BioWorld Online - BioWorld Online Aqueous skin prep solution increases topical tx effects.(Moore Unique... - Nov 1, 2007 In a recent study, the Hydroglide Dermatological Enhancer caused the steroid foam LUXIQ to penetrate 2 to 2.5 times more at all skin levels, Dr. Moore says. ... $4.95 - Dermatology Times - ECNext Connetics Names Luis Pena Vice President, Project Management; … - Aug 22, 2005 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... RedOrbit Stiefel Laboratories Announces Expiration of Hart-Scott-Rodino... - Jul 29, 2008 Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R) Cream; Olux(R) (clobetasol propionate) Foam, ... Lifescience-online Stiefel acquisition marries technology, marketing: foam vehicle... - Mar 1, 2007 Stiefel's Olux (clobetasol propionate), Luxiq (betamethasone) and Evoclin (clindamycin phosphate) already use Con netics' HF alcohol-based foam vehicle, ... $4.95 - Dermatology Times - ECNext A Skin-Win Scenario - Apr 5, 2005 Nearly $1 billion of that market is made up of topical steroids like Connetics' Luxiq for severe dandruff (estimated to total 14% of Connetics' 2005 sales, ... Smartmoney.com Connetics Receives Notice from Nasdaq Due to Late Filing of Form 10... - May 19, 2006 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin) ... Free with registration - Business Wire - AccessMyLibrary.com Q3 2005 Connetics Earnings Conference Call - Part 2. - Nov 1, 2005 Could you describe the magnitude of the price increases that you guys took in the third quarter on the products, OLUX, Luxiq, Soriatane [inaudible]? ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Connetics Licenses Technology for the Treatment of Hyperhidrosis. - Mar 7, 2006 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... Free with registration - Business Wire - AccessMyLibrary.com Daiichi Sankyo.(Update) | Article from Medical Marketing & Media | … - Dec 1, 2008 Olux, Olux-E, Luxiq, Soritane; Daiichi-Sankyo: CS-8663; Eisai, Inc.: Inavra ... Medical Marketing & Media. Article: Cardiovascular.(PIPELINE 2009) ... Pay-Per-View - Medical Marketing & Media - HighBeam Research Connetics Announces 2005 Analyst and Investor Day in New York City; … - Mar 10, 2005 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... Free with registration - Business Wire - AccessMyLibrary.com UREX Energy Corp. Upgraded to $3.00 per Share. - Nov 9, 2006 ...and scalp and non-scalp psoriasis; Soriatane, an oral retinoid, to treat severe psoriasis in adults; and Luxiq Foam, a midpotency topical steroid, ... Free with registration - M2 Presswire - AccessMyLibrary.com Connetics Names Shari Geffon Senior Director, Project Management; … - Jun 5, 2006 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... Free with registration - Business Wire - AccessMyLibrary.com Connetics Names Sunil Patel Vice President, Corporate Development … - May 8, 2006 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... Genetic Engineering News - Genetic Engineering News (press release) Connetics Files Citizen Petition for Soriatane With the FDA; Emphasize... - Apr 3, 2006 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... Genetic Engineering News - Genetic Engineering News (press release) Connetics Names Tim Pergram Regional Sales Director; Reports New … - May 30, 2006 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... Free with registration - Business Wire - AccessMyLibrary.com Connetics Reports Positive Results From Second Phase III Clinical... - Aug 28, 2006 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin) ... Free with registration - Business Wire - AccessMyLibrary.com Connetics Names Doris Boesch Director, Stability Programs; Reports … - Mar 24, 2006 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... Free with registration - Business Wire - AccessMyLibrary.com Connetics Names Liang Liu Associate Director, DMPK/Bioanalytical; … - Apr 24, 2006 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... Free with registration - Business Wire - AccessMyLibrary.com Q2 2006 Connetics Earnings Conference Call - Part 1. - Aug 15, 2006 Roughly 60% of that reduction went to Soriatane, about 25% to OLUX and the balance Luxiq. In the second quarter, the revenues benefited by about $2.9 ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Connetics Announces Results of Special Stockholders Meeting - Dec 20, 2006 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin) ... Genetic Engineering News - Genetic Engineering News (press release) Connetics Names Cynthia Canup Director, Sales Training; Reports New … - Jun 1, 2006 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... Genetic Engineering News - Genetic Engineering News (press release) Connetics Reports Preliminary Results for First Quarter 2006; Company... - May 3, 2006 ...including Soriatane(R) sales of $19.0 million, OLUX(R) sales of $14.1 million, Evoclin(R) sales of $8.0 million and Luxiq(R) sales of $6.2 million. ... Genetic Engineering News - Genetic Engineering News (press release) Connetics Taps New M&A Pro.(appoints Sunil Patel) - May 22, 2006 Its products include scalp treatments Luxiq and Olux, an acne treatment called Evoclin and a psoriasis treatment called Soriatane. ... Free with registration - Mergers & Acquisitions Report - AccessMyLibrary.com Stiefel plans $640m acquisition of Connetics. - Oct 30, 2006 The company turned its attention to such products as Olux (clobetasol propionate) and Luxiq (betamethasone valerate) foams, marketed for scalp dermatoses. ... Free with registration - BioWorld Week - AccessMyLibrary.com Connetics Taps New M&A Pro. - May 22, 2006 Its products include scalp treatments Luxiq and Olux, an acne treatment called Evoclin and a psoriasis treatment called Soriatane. What is notable about the ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Connetics Reports New Option Grants under Nasdaq Marketplace Rule … - Sep 5, 2006 The Company's commercial products are OLUX (clobetasol propionate) Foam, 0.05%; Luxiq (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin) ... Genetic Engineering News - Genetic Engineering News (press release) FDA approves Connetics' eczema drug. - Sep 20, 2006 Connetics already markets Luxiq, a mid-potency drug, and Olux, a super-high potency drug. Eczema, or atopic dermatitis, is a chronic skin disorder with ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com Connetics Names Kari Walsh Director, Compensation, Benefits and … - Jun 19, 2006 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... Genetic Engineering News - Genetic Engineering News (press release) Connetics Presents Eight Scientific Posters at the 64th Annual... - Mar 2, 2006 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... Free with registration - Business Wire - AccessMyLibrary.com Connetics in Compliance With Nasdaq Listing Requirements. - Aug 1, 2006 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin) ... Free with registration - Business Wire - AccessMyLibrary.com Ethnic pediatric patients benefit from tailored treatment plan.(PEDIAT... - Mar 1, 2006 For patients who like mousse, there is a great product called Luxiq (Connetics) foam," Dr. Trowers says. If the doctor don't ask, he or she is basing ... Free with registration - Dermatology Times - AccessMyLibrary.com Connetics buys PediaMed sales org.(PediaMed Pharmaceuticals Inc.)( … - Jan 16, 2006 ...selling Evoclin (clindamycin) Foam, 1%, a topical treatment for acne, and Luxiq (betamethasone valerate) Foam, 0.12%, a topical steroid for dermatoses. ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Drug/Medical Device Report Stiefel Laboratories, Inc. - Feb 23, 2008 Connectics Luxiq (Betamethasone. Valerate) Foam. Relief Of The Inflammatory. And Pruritic Manifestations Of. Corticosteroid-Responsive ... $70.00 - Revere Reports - Revere Connetics Receives FDA Non-Approvable Letter for Velac; Conference … - Jun 13, 2005 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... $4.95 - Business Wire - ECNext Press Release: Stiefel Laboratories, Inc. Successfully Completes... - Aug 5, 2008 Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R) Cream; Olux(R) (clobetasol propionate) Foam, ... Pay-Per-View - PR Newswire - HighBeam Research Connetics to Resume Extina Development with New Phase III Trial. - Jun 8, 2005 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... $4.95 - Business Wire - ECNext Connetics Commences Phase III Clinical Trial With Primolux for Atopic... - Mar 24, 2005 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... $4.95 - Business Wire - ECNext StreetInsider.com Spotlight of Urex Energy Corporation. - Oct 30, 2006 ...and scalp and non-scalp psoriasis; Soriatane, an oral retinoid, to treat severe psoriasis in adults; and Luxiq Foam, a midpotency topical steroid, ... $4.95 - M2 Presswire - ECNext VIASPACE Subsidiary, DMFC , Completes Development of Fuel Cell - Oct 30, 2006 ...and scalp and non-scalp psoriasis; Soriatane, an oral retinoid, to treat severe psoriasis in adults; and Luxiq Foam, a midpotency topical steroid, ... Pay-Per-View - M2 Presswire - Factiva, from Dow Jones Press Release: Stiefel Laboratories, Inc. Announces Expiration of... - Jul 29, 2008 Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R) Cream; Olux(R) (clobetasol propionate) Foam, ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Onyx Pharmaceuticals Names Thomas G. Wiggans to Its … - Mar 10, 2005 Complete ... with silvery white scales. The study was funded by the Connetics Corporation, which markets Luxiq. Henry Ford Health System is one ... ... Pay-Per-View - PR Newswire - HighBeam Research Connetics Announces 2005 Discovery Day Event to Be Webcast Live … - Sep 15, 2005 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... $4.95 - Business Wire - ECNext Centron: organic growth continued to fuel revenue for this relatively... - Jul 1, 2008 ...and Stiefel Laboratories (Soriatane, Verdeso, Olux, Olux-E, and Luxiq). "Organic growth has been a pattern," McLaughlin says. "It's good for everybody." ... Pay-Per-View - Medical Marketing & Media - HighBeam Research Press Release: Stiefel Laboratories, Inc. Commences Tender Offer to … - Jul 8, 2008 Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R) Cream; Olux(R) (clobetasol propionate) Foam, ... Pay-Per-View - PR Newswire - HighBeam Research Connetics Names Greg Vontz President; CEO Tom Wiggans to Be Named … - Feb 17, 2005 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... $4.95 - Business Wire - ECNext Connetics Reports New Option Grants under Nasdaq Marketplace Rule … - Sep 29, 2006 The Company's commercial products are OLUX(clobetasol propionate) Foam, 0.05%; Luxiq(betamethasone valerate) Foam, 0.12%; Soriatane([R]) (acitretin) ... $4.95 - Business Wire - ECNext DRUG NAMES A game of Scrabble? - Sep 26, 2006 It is battling for your attention with other products called Zofran, Zmax, Xeloda, Marqibo, Hyzaar, NovoNorm and Luxiq. These are just the brand names of ... Pay-Per-View - Daily Express - Factiva, from Dow Jones Connetics Names Claudette Macmillan Senior Director, Financial … - Oct 1, 2005 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... $4.95 - Business Wire - ECNext Connetics in Compliance With Nasdaq Listing Requirements. - Aug 1, 2006 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin) ... $4.95 - Business Wire - ECNext Press Release: Ventiv Announces New Partnership with Connetics … - Apr 14, 2005 ...education of Connetics' top dermatological products Evoclin(R), Luxiq(R) and OLUX(R) to a targeted group of primary care physicians and pediatricians. ... Pay-Per-View - PR Newswire - HighBeam Research Connetics Names Scott W. Meggs Senior Director, Corporate Counsel; … - Aug 5, 2005 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... $4.95 - Business Wire - ECNext Connetics Founder Eugene A. Bauer Steps Down as Director after 11 … - Oct 17, 2005 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... $4.95 - Business Wire - ECNext Favorable Soriatane Cost-Effectiveness Analysis is Published in... - May 11, 2005 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... $4.95 - Business Wire - ECNext Connetics Names Stefan C. Weiss, MD, Senior Medical Director; Reports... - Jul 12, 2005 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... $4.95 - Business Wire - ECNext SPOTLIGHT on : FAVORED Inc. (PinkSheets: FVRD). - Oct 26, 2006 ...and scalp and non-scalp psoriasis; Soriatane, an oral retinoid, to treat severe psoriasis in adults; and Luxiq Foam, a midpotency topical steroid, ... $4.95 - M2 Presswire - ECNext Connetics Files Resale Registration Statement Covering Its 2.00% … - Jun 20, 2005 The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) ... $4.95 - Business Wire - ECNext Brand Names/Synonyms: Luxiq is also known by the following brand names and/or synonymsAlphatrex; Bebate; Becort; Bedifos; Beta-Methasone; Beta-Methasone Alcohol; Beta-Val; Betacorlan; Betacortril; Betaderm; Betadexamethasone; Betafluorene; Betamamallet; Betametasona [Inn-Spanish]; Betametasone [Dcit]; Betamethasone; Betamethasone Alcohol; Betamethasone Base; Betamethasone Cream; Betamethasone Dipropionate; Betamethasone Sodium Phosphate; Betamethasone Valearate; Betamethasone Valerate; Betamethasone [Usan:Ban:Inn:Jan]; Betamethasonum [Inn-Latin]; Betamethasonvalerat Mikron.; Betamethazone; Betapredol; Betasolon; Betatrex; Betnelan; Betsolan; Celestene; Celestone; Celestone Syrup and Tablets; Cidoten; Dermabet; Desacort-Beta; Diproderm; Diprolene; Diprolene Af; Diprosone; Flubenisolone; HSDB 3015; Hormezon; Lotrisone; Luxiq; Luxiqo; Maxivate; Methazon; Rinderon; Rinderon A; Sch 4831; Uticort; Valisone; Valnac; Visubeta Drug Category: Luxiq is categorized under the following by the FDA: Corticosteroid; Glucocorticoids; Anti-inflammatory, steroidal; Immunosuppressant; ATC:A07EA04; ATC:C05AA05; ATC:D07AC01; ATC:D07XC01; ATC:H02AB01; ATC:R01AD06; ATC:R03BA04; ATC:S01BA06; ATC:S01CB04; ATC:S02BA07; ATC:S03BA03 Dosage Forms: Syrup; Tablet Absorption: Minimal if applied topically Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |